[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lei ZHAO\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100620006","phase-2-sintilimab-combined-with-stereotactic-body-radiotherapy-as-neoadjuvant-therapy-for-resectable-hepatocellular-100620006",false,"NCT07352007","Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular","A Prospective, Randomized Controlled, Phase II Study of Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Written informed consent must be provided and signed prior to the implementation of any trial-related procedures.\n2. Male or female subjects aged ≥18 years and ≤75 years.\n3. ECOG PS score of 0-1.\n4. BCLC 0-B.\n5. Diagnosed with HCC according to the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2019 Edition).\n6. CNLC Stage IA-IIB.\n7. Child-Pugh score of ≤7.\n8. No prior systemic antitumor therapy for hepatocellular carcinoma.\n9. Assessed as suitable for R0 resection surgery.\n10. Assessed as having no contraindications to SBRT and immunotherapy.\n11. Estimated life expectancy of \\>3 months.\n12. At least one measurable lesion according to RECIST 1.1 or mRECIST criteria.\n13. Adequate organ and bone marrow function, defined as follows:a) Hematology: Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL; Platelet count (PLT) ≥75×10⁹\u002FL; Hemoglobin (HGB) ≥9.0 g\u002FdL.b) Liver function: Serum total bilirubin (TBIL) ≤3 × upper limit of normal (ULN); Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤5 × ULN; Serum albumin ≥28 g\u002FL.c) Renal function: Serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance (CCr) ≥ 50 mL\u002Fmin (Cockcroft-Gault formula); Urinalysis shows urine protein \\\u003C2+; For patients with baseline urinalysis showing urine protein ≥2+, a 24-hour urine collection must demonstrate 24-hour urine protein \\\u003C1 g.d) Coagulation function: International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.\n14. For subjects with acute or chronic active hepatitis B or C infection, continuous antiviral therapy must be administered during the study period.\n15. For female subjects of childbearing potential, a negative urine or serum pregnancy test must be confirmed within 3 days prior to receiving the first dose of the study drug (Cycle 1, Day 1). If a urine pregnancy test is inconclusive, a blood pregnancy test is required. Non-childbearing potential is defined as being post-menopausal for at least 1 year, or having undergone surgical sterilization or hysterectomy.\n16. If there is a risk of conception, all subjects (both male and female) must use highly effective contraceptive methods (with a failure rate of \\\u003C1% per year) throughout the entire treatment period and for at least 120 days after the last dose of the study drug (or 180 days after the last dose of chemotherapy). Estimated life expectancy ≥12 weeks.\n\nExclusion Criteria:\n\n1. History of any histologically\u002Fcytologically confirmed malignancy other than HCC.\n2. History of hepatic encephalopathy, or history of liver transplantation.\n3. Presence of any extrahepatic metastatic lesions.\n4. Prior receipt of any systemic antitumor therapy for HCC, including treatment with antibodies such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 agents.\n5. Acute or chronic active hepatitis B or C infection, defined as: Hepatitis B virus (HBV) DNA \\>2000 IU\u002FmL or 10⁴ copies\u002FmL; Hepatitis C virus (HCV) RNA \\>10³ copies\u002FmL; Co-positive for Hepatitis B surface antigen (HBsAg) and anti-HCV antibody.\n6. Radiotherapy received within 3 weeks prior to the first dose.\n7. Human Immunodeficiency Virus (HIV) infection (positive HIV 1\u002F2 antibodies) or known active syphilis infection.\n8. Severe infections that are either active or poorly controlled clinically.\n9. Active autoimmune disease that required systemic treatment within the past 2 years prior to the first dose.\n10. Known history of primary immunodeficiency. The presence of autoimmune antibodies alone requires the investigator's judgment to confirm the presence of an autoimmune disease.\n11. Use of immunosuppressive medication within 4 weeks prior to the first dose, with the exception of intranasal, inhaled, or other routes of locally administered corticosteroids, or systemic corticosteroids at physiological doses (i.e., not exceeding 10 mg\u002Fday prednisone or an equivalent dose of other corticosteroids). Temporary use of corticosteroids for conditions such as asthma or COPD for dyspnea is permitted.\n12. Administration of any live attenuated vaccine within 4 weeks prior to the first dose or planned administration during the study period.\n13. Any local therapy for liver cancer received within 4 weeks prior to the first dose.\n14. Diagnosis of another malignancy within 5 years prior to the first dose, with the exception of radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and\u002For carcinoma in situ that has undergone radical resection. If another malignancy or HCC was diagnosed more than 5 years prior to the first dose, pathological or cytological confirmation is required for any recurrent or metastatic lesions.\n15. Known allergy to any component of the Sintilimab formulation; or history of severe allergic reactions to other monoclonal antibodies or tyrosine kinase inhibitors.\n16. Treatment received as part of another clinical trial within 4 weeks prior to the first dose.\n17. Female patients who are pregnant or breastfeeding.\n18. Any other acute or chronic disease, psychiatric disorder, or abnormal laboratory test value that may lead to the following outcomes: increased risk associated with study participation or study drug administration, interference with the interpretation of study results, and based on the investigator's judgment, makes the patient unsuitable for participation in this study.","ALL","18 Years","75 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is a prospective, randomized controlled, phase II trial evaluating the efficacy and safety of neoadjuvant therapy with Sintilimab combined with SBRT in patients with resectable hepatocellular carcinoma.\n\nAfter meeting the inclusion and exclusion criteria and providing informed consent, eligible subjects will be randomly assigned to the experimental group or the control group:\n\n* Experimental Group: Subjects will receive Sintilimab 200 mg via intravenous infusion on day 1 of each 3-week cycle, for a total of two cycles. This will be combined with SBRT, administered as 8 Gy per fraction for 3 fractions on days 1, 3, and 5. Surgery will be performed 4-6 weeks after the last treatment, following the assessment of the patient's condition. Postoperative adjuvant therapy with Sintilimab monotherapy (200 mg Q3W) will be administered until disease recurrence, death, intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, or other protocol-specified reasons occur, for a maximum of one year.\n* Control Group:Subjects will undergo surgery directly. Postoperative adjuvant therapy with Sintilimab monotherapy (200 mg Q3W) will be administered until disease recurrence, death, intolerable toxicity, withdrawal of informed consent, initiation of new antitumor therapy, or other protocol-specified reasons occur, for a maximum of one year.",[27],"HCC","NOT_YET_RECRUITING","2026-01-11",{"date":31,"type":32},"2026-01-20","ACTUAL",{"date":34,"type":21},"2025-12-28",{"date":36,"type":21},"2031-01-20",{"name":38,"class":39},"Lei ZHAO","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100585565","phase-2-efficacy-and-safety-of-sintilimab-combined-with-lenvatinib-and-haic-for-neoadjuvant-therapy-of-borderline-resectable-hcc-100585565","NCT06904014","Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC","Exploratory Study on the Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Sign a written informed consent before the implementation of any trial-related procedures.\n2. Male or female, aged ≥18 years and ≤70 years.\n3. ECOG PS score of 0-2.\n4. Diagnosed with HCC according to the Diagnosis and Treatment Guidelines for Primary Liver Cancer in China (2019 Edition).\n5. CNLC stage IIIa, with vascular invasion but no extrahepatic metastasis.\n6. Child-Pugh score of A\u002FB.\n7. Portal vein tumor thrombus is classified as type 1-2 according to the Japanese VP classification or type I-II according to the Program classification.\n8. No previous systemic anti-tumor treatment for hepatocellular carcinoma and eligible for R0 resection.\n9. Expected survival time \\> 3 months.\n10. At least one measurable lesion according to RECIST 1.1 or mRECIST criteria.\n11. Adequate organ and bone marrow function, as follows:\n\n1\\) Blood routine: absolute neutrophil count (ANC) ≥ 1.5×109\u002FL; platelet count (PLT) ≥ 75×109\u002FL; hemoglobin content (HGB) ≥ 9.0 g\u002FdL.\n\n2\\) Liver function: serum total bilirubin (TBIL) ≤ 3×ULN; alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 5×ULN; serum albumin ≥ 28 g\u002FL.\n\n3\\) Renal function: serum creatinine (Cr) ≤ 1.5×ULN or clearance of creatinine (CCr) ≥ 50 mL\u002Fmin (Cockcroft-Gault formula); urine routine test shows urine protein \\\u003C 2+; for patients with urine protein ≥ 2+ at baseline, 24-hour urine collection is required and 24-hour urine protein quantification \\\u003C 1 g.\n\n4\\) Coagulation function: international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5×ULN.\n\n12\\. For patients with acute or chronic active hepatitis B or C, continuous antiviral treatment is required during the study period.\n\n13\\. For female subjects of childbearing age, a urine or serum pregnancy test must be negative within 3 days before the first administration of the study drug (day 1 of cycle 1). If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Non-childbearing age females are defined as those who have been postmenopausal for at least 1 year, or have undergone surgical sterilization or hysterectomy.\n\n14\\. If there is a risk of pregnancy, all subjects (regardless of gender) must use a contraceptive method with a failure rate of less than 1% throughout the treatment period until 120 days after the last administration of the study drug (or 180 days after the last administration of chemotherapy drugs). Expected survival time ≥ 12 weeks.\n\nExclusion Criteria:\n\n1. Previously histologically\u002Fcytologically confirmed liver cancer with components such as fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, etc.\n2. History of hepatic encephalopathy or liver transplantation.\n3. Clinical symptoms requiring drainage of pleural effusion, ascites, or pericardial effusion.\n4. Acute or chronic active hepatitis B or C infection, with HBV DNA \\> 2000 IU\u002Fml or 104 copies\u002Fml; HCV RNA \\> 103 copies\u002Fml; positive for both hepatitis B surface antigen (HbsAg) and anti-HCV antibody.\n5. Central nervous system metastasis.\n6. Esophageal or gastric variceal bleeding events due to portal hypertension within the past 6 months. Known severe (G3) varices on endoscopy within 3 months before the first dose. Evidence of portal hypertension (including splenomegaly on imaging), and high bleeding risk as assessed by the investigator.\n7. Any life-threatening bleeding events within the past 3 months, including those requiring blood transfusion, surgery or local treatment, or continuous drug treatment.\n8. Venous or arterial thromboembolic events within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis or any other serious thromboembolic events. Patients with stable thrombosis after conventional anticoagulation treatment, such as those with implanted venous access ports or catheter-related thrombosis, or superficial vein thrombosis, are excluded. Prophylactic use of low-dose low-molecular-weight heparin (e.g., enoxaparin 40 mg\u002Fday) is allowed.\n9. Use of aspirin (\\> 325 mg\u002Fday) or other known platelet function inhibitors such as dipyridamole or clopidogrel for 10 consecutive days within 2 weeks before the first dose.\n10. Uncontrolled hypertension, with systolic blood pressure \\> 150 mmHg or diastolic blood pressure \\> 90 mmHg after optimal medical treatment, or history of hypertensive crisis or hypertensive encephalopathy.\n11. Symptomatic congestive heart failure (NYHA class II-IV). Symptomatic or poorly controlled arrhythmia. History of congenital long QT syndrome or corrected QTc \\> 500 ms (calculated using the Fridericia method) at screening.\n12. Severe bleeding tendency or coagulation disorders, or currently undergoing thrombolytic therapy.\n13. History of gastrointestinal perforation and\u002For fistula within the past 6 months, history of intestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive intestinal resection (partial colectomy or extensive small bowel resection, concurrent with chronic diarrhea), Crohn's disease, ulcerative colitis, or long-term chronic diarrhea.\n14. Received radiotherapy within 3 weeks before the first dose. For patients who received radiotherapy more than 3 weeks before the first dose, all of the following conditions must be met to be eligible for inclusion: no current radiotherapy-related toxicities, no need for glucocorticoids, and exclusion of radiation pneumonitis, radiation hepatitis, radiation enteritis, etc.\n15. History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, or severe lung function impairment.\n16. Human immunodeficiency virus (HIV) infection (HIV 1\u002F2 antibody positive), or known syphilis infection.\n17. Active or poorly controlled severe infection. Severe infection within 4 weeks before the first dose, including but not limited to hospitalization due to infection, bacteremia, or complications of severe pneumonia.\n18. Active or poorly controlled autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years before the first dose. Use of replacement therapy (e.g., thyroid hormone, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is allowed. A known history of primary immunodeficiency. Patients with only positive autoimmune antibodies need to be confirmed by the investigator as having no autoimmune disease.\n19. Use of immunosuppressive drugs within 4 weeks before the first dose, excluding nasal sprays, inhalation or other local glucocorticoids or physiological doses of systemic glucocorticoids (i.e., no more than 10mg\u002Fday of prednisone or equivalent doses of other glucocorticoids), and temporary use of glucocorticoids for the treatment of breathing difficulties due to asthma, chronic obstructive pulmonary disease, etc. is allowed.\n20. Receipt of live attenuated vaccines within 4 weeks before the first dose or planned during the study period.\n21. Receipt of local treatment for liver cancer within 4 weeks before the first dose.\n22. Receipt of traditional Chinese medicine with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin, except for local use to control pleural or ascitic fluid) within 2 weeks before the first dose.\n23. Uncontrolled or uncorrectable metabolic disorders or other non-malignant organ diseases or systemic diseases or secondary reactions of cancer that may lead to higher medical risks and\u002For uncertainty in survival evaluation.\n24. Diagnosis of other malignancies within 5 years before the first dose, excluding skin basal cell carcinoma, skin squamous cell carcinoma, and\u002For in situ carcinoma that have been completely resected. If other malignancies or liver cancer were diagnosed more than 5 years before the first dose, pathological or cytological diagnosis of recurrent or metastatic lesions is required.\n25. Previous receipt of any anti-PD-1 antibody, anti-PD-L1\u002FL2 antibody, anti-CTLA4 antibody, or other immunotherapy.\n26. Known allergy to any component of sintilimab, lenvatinib, or chemotherapy drugs; or previous severe allergic reactions to other monoclonal antibodies or tyrosine kinase inhibitors.\n27. Receipt of treatment in other clinical trials within 4 weeks before the first dose.\n28. Pregnant or lactating female patients.\n29. Other acute or chronic diseases, mental disorders, or abnormal laboratory test values that may lead to the following results: increased risks associated with study participation or administration of the study drug, or interference with the interpretation of study results, and the patient is judged by the investigator as not eligible to participate in this study.","70 Years",{"count":50,"type":21},40,[24],"This study is a single-center, randomized controlled exploratory Phase II clinical trial, aiming to assess the efficacy and safety of sintilimab combined with lenvatinib and HAIC for two cycles followed by surgery compared with direct surgery in patients with borderline resectable hepatocellular carcinoma.\n\nAfter signing the informed consent and meeting the inclusion and exclusion criteria, the eligible subjects were randomly divided into the experimental group and the control group:\n\n* Subjects in the experimental group received 200 mg of sintilimab by intravenous infusion on the first day of every 3 weeks. Lenvatinib 8 mg was orally administered once daily, combined with the HAIC-FOLFOX regimen. After two cycles, the patients' conditions were evaluated for surgery.\n* Subjects in the control group underwent surgery directly.\n\nBoth groups of subjects received sintilimab monotherapy as adjuvant treatment for half a year (a total of 8 cycles) after surgery. The treatment was terminated if there was disease recurrence, death, intolerable toxicity, withdrawal of informed consent, initiation of new anti-tumor treatment, or other reasons stipulated in the protocol.",[27],"RECRUITING","2025-03-30",{"date":57,"type":32},"2025-04-01",{"date":59,"type":32},"2023-10-25",{"date":61,"type":21},"2029-06-30",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":40},"100538878","phase-2-perioperative-treatment-of-resectable-intrahepatic-cholangiocarcinoma-with-the-combination-of-adebrelimab-and-apatinib-and-haic-100538878","NCT06296563","Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC","A Single Arm, Exploratory Clinical Study on the Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC","Inclusion Criteria:\n\n* 1\\. Pathological diagnosis as malignant tumor of Intrahepatic Cholangiocarcinoma;\n* 2\\. According to the UICC\u002FAJCC TNM staging system (8th edition, 2017), resectable subjects were classified as Ib-IIIb stages;\n* 3\\. aged ≥ 18 years at the time of signing the Informed consent form (ICF);\n* 4\\. Expected survival time\\>3 months;\n* 5\\. Both men and women are eligible;\n* 6\\. The patient's Eastern Oncology Collaborative Group (ECOG) physical condition score is 0 or 1;\n* 7\\. No serious complications, such as hypertension, coronary heart disease, or history of mental illness, and no history of severe allergies; Non pregnancy and non lactation period;\n* 8\\. The organ and blood system functions of the subjects meet the following requirements:\n\n  1. Absolute neutrophil count (ANC) ≥ 1.5 × 10 \\^ 9\u002FL;\n  2. Platelet count ≥ 75 × 10 \\^ 9\u002FL;\n  3. Hemoglobin ≥ 90 g\u002FL;\n  4. Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN);\n  5. Aspartate aminotransferase (AST) and alanine aminotransferase ≤ 2.5 x ULN;\n  6. Albumin ≥ 3g\u002FdL\n  7. Creatinine ≤ 1.5 x ULN\n* 9\\. The subjects can understand and sign the informed consent form to participate in the experimental study; Good compliance.\n* 10\\. Participants who have not undergone any local or systemic treatment for tumors in the past, and have undergone radical resection surgery for biliary tract cancer before recurrence for at least 2 years, can be included;\n* 11\\. Subjects with potential fertility need to use a medically approved contraceptive measure (such as an intrauterine device, contraceptive pill, or condom) during the study treatment period and within one month after the end of the study treatment period; And within 72 hours before enrollment, the serum or urine HCG test must be negative and must be non lactating;\n\nExclusion Criteria:\n\n* 1\\. Patients who received PD-1, PD-L1, PD-L2, or CTLA-4 inhibitors before enrollment, or patients who directly received another stimulating or co inhibitory T cell receptor (such as CTLA-4, CD137);\n* 2\\. Use any other investigational drugs within 4 weeks prior to enrollment;\n* 3\\. Any history of active autoimmune diseases or autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism after hormone replacement therapy); Children with asthma who have completely improved in adulthood and do not require any intervention can be included, but patients who require intervention with bronchodilators cannot be included;\n* 4\\. Congenital or acquired immunodeficiency, such as infection with human immunodeficiency virus (HIV), active hepatitis B (HBV DNA 500IU\u002Fml), hepatitis C (hepatitis C antibody positive, HCV-RNA above the detection limit of the analysis method), or co infection with hepatitis B and hepatitis C;\n* 5\\. Serious infection (such as intravenous infusion of antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first administration, or unexplained fever\\>38.5 ° C occurred during screening\u002Fbefore the first administration;\n* 6\\. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* 7\\. Suffering from uncontrollable mental illness;\n* 8\\. The simultaneous occurrence of serious and\u002For uncontrollable diseases may affect the participation of the study, such as unstable angina pectoris, myocardial infarction within 6 months, unstable symptomatic arrhythmia, symptomatic congestive heart failure, poorly controlled diabetes, serious activities, uncontrollable infection after insufficient biliary drainage (such as tumor blocking the bile duct);\n* 9\\. Pregnancy (positive pregnancy test) or lactation period;\n* 10\\. Other cancers that have occurred in the past (within the past 5 years) or simultaneously, excluding non melanoma skin cancer and in situ cancer;\n* 11\\. History of allergy or hypersensitivity to any investigational drug;\n* 12\\. Currently abusing alcohol or illegal drugs;\n* 13\\. Unable or unwilling to sign informed consent form.",{"count":71,"type":21},20,[24],"The goal of this clinical trial is to explore the efficacy and safety of combined infusion chemotherapy with Adebrelimab and Apatinib in the perioperative treatment of resectable intrahepatic cholangiocarcinoma patients. The main question it aims to answer are:\n\nHow to improve the survival of patients with intrahepatic cholangiocarcinoma and prolong the recurrence time after surgery.\n\nParticipants will receive receive neoadjuvant therapy with Adebrelimab combined with apatinib and FOLFOX-HAIC for 2 cycles (1 treatment cycle every 21 days, apatinib only used for the first cycle), and surgery was performed 14-28 days after the end of treatment. After 28 days of surgery, patients will continue to receive adjuvant treatment with Adebrelimab combined with apatinib for a maximum of one year.",[75],"Intrahepatic Cholangiocarcinoma","2024-04-15",{"date":78,"type":32},"2024-04-17",{"date":80,"type":32},"2024-03-01",{"date":82,"type":21},"2029-03-01",{"name":38,"class":39},""]